The positive stock movement for Ascendis Pharma is likely due to the potential revenue and market expansion opportunities presented by the exclusive license agreement with Teijin Limited. This deal is significant as it opens up the Japanese market for Ascendis Pharma's rare disease drugs, which can lead to increased sales and positive investor sentiment in the short term.